Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06748053 | A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma | PHASE2 | ACTIVE NOT_RECRUITING | 307 | — | — | Feb 10, 2025 | Sep 9, 2027 | May 22, 2026 | 133 | United States, Bulgaria +7 |
| Arm | Type | Description |
|---|---|---|
| Part A: Dose Finding - GSK5784283 | EXPERIMENTAL | - |
| Part A: Dose Finding - Placebo | EXPERIMENTAL | - |
| Part B: Extended Dosing - GSK5784283 | EXPERIMENTAL | - |
| Part B: Extended Dosing - Placebo | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| GSK5784283 | DRUG | GSK5784283 will be administered. |
| Placebo | DRUG | Placebo will be administered. |
Inclusion Criteria: Participants are eligible to be included in the study only if all of the following criteria apply: * Informed Consent: Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and this p...